Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: $73.3 million Upfront Cash: Undisclosed

            Deal Type: Collaboration June 02, 2021

            Details:

            Under the agreement, AstraZeneca will provide research funding and Proteros will be eligible for success-based research, development, and commercial milestone payments up to 62 million EUR plus tiered royalties on annual net sales.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 26, 2021

            Details:

            The partnership leverages Evotec’s proprietary PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging with the integrated data analysis platform PanHunter.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: $160.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration March 22, 2021

            Details:

            The collaboration will leverage Evotec’s extensive RNA targeting platform to optimally identify promising RNA sequences to target with small molecule ligands that can be developed into potentially first-in-class therapeutics.